NeuroSense Therapeutics Ltd.
NRSN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001875091
No open-market purchases or sales by NeuroSense Therapeutics Ltd. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $285.7K in total; no superinvestor holds it.
Other share classesNRSNW
Q1 2022 vs. Q4 2021
How the institutions holding NeuroSense Therapeutics Ltd. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 5 | 9 | +4 |
| Shares | 155.0K | 169.0K | +14.0K (+9.1%) |
| Value | $380.0K | $694.0K | +$314.0K (+82.6%) |
New holders (7)
Institutions that held NeuroSense Therapeutics Ltd. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ikarian Capital, LLC | 100,000 | $397.0K | 0.12% |
| Jane Street Group, LLC | 43,498 | $173.0K | 0.00% |
| Bank of Montreal | 10,000 | $65.0K | 0.00% |
| Boothbay Fund Management, LLC | 12,170 | $48.0K | 0.00% |
| FNY Investment Advisers, LLC | 1,000 | $3.00K | 0.00% |
| Citigroup Inc | 10 | $0 | 0.00% |
| Royal Bank of Canada | 125 | $0 | 0.00% |
Sold out (3)
Institutions that held NeuroSense Therapeutics Ltd. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Hudson Bay Capital Management LP | 75,000 | $184.0K |
| Citadel Advisors LLC | 55,119 | $135.0K |
| Warberg Asset Management LLC | 15,501 | $38.0K |